Report Company Directory

Glencore plc

• Glencore Plc "What's next after RIO?" (Neutral) Allsop by UBS AG
• STEEL CHINA, STRATEGY, GLENTINTO, B, APAM by BNP Paribas
• First Read: Daily Commodities Note "Rio Tinto walk away from Glencore" Shaw by UBS AG
• "GlenTinto" - and it was all for naught by BNP Paribas
• GLEN, MT, US AUTO, STEEL US by BNP Paribas
• DRC stake sale helpful for discussions with RIO by BNP Paribas
• CHINA PMI, STRATEGY, RIO/GLEN by BNP Paribas
• GREEN STEEL, STEEL EU, MINING EQUIPMENT, GLEN, ANTO, NDA by BNP Paribas
• 4Q25 production first take - production/pricing solid, cost lower by BNP Paribas
• Teck Resources Ltd "Anglo-Teck: Copper deep-dive" (Buy) Allsop by UBS AG

GLENFARNE MERGER CORP

• Glenfarne Merger Corp. Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination by BusinessWire

Glenmark Pharmaceuticals Limited

• Glenmark Pharmaceuticals Limited: 1 director by SmartInsider
• With a more favourable environment, GLENMARK PHARMACEUTICALS improves to Slightly Positive by TheScreener
• LUPN.BO: Lupin Ltd - Quick Take - Margin weak despite strong US sales; Specialty restructuring announced by Credit Suisse
• Monthly LMI Update Independent Investment Research by Independent Investment Research
• Glenmark Pharmaceuticals' Q3FY20 results (Outperformer) - Good quarter; compelling valuations by IDFC Securities
• Feasibility Study Results in December to be a Catalyst for this Junior by Fundamental Research
• Glenmark Pharmaceuticals' Q2FY20 results (Upgrade to Outperformer) - Strong performance driven by US & India backed by cost optimization by IDFC Securities
• MOSL: GLENMARK PHARMA (Neutral)-Traction improves in US/LATAM segment by Motilal Oswal
• Glenmark Pharmaceuticals' Q1FY20 results (Neutral) - Another soft quarter; Sluggish US performance by IDFC Securities
• MOSL: GLENMARK PHARMA (Neutral)-Miss on all fronts led by muted US/ROW sales & higher interest/tax rate by Motilal Oswal

GLENMEDE FUND INC

GLENMOORE CAPITAL REIT